Results 151 to 160 of about 60,708 (285)

Sympathetic stimulation can compensate for hypocalcaemia‐induced bradycardia in human and rabbit sinoatrial node cells

The Journal of Physiology, EarlyView.
Abstract figure legend AC: adenylyl cyclase, APT: adenosine triphosphate, AMP: adenosine monophosphate, cAMP: cyclic adenosine monophosphate, PDE: phosphodiesterase, PKA: protein kinase A, PPT: protein phosphatase, P: phosphorylation, RyR: ryanodine receptor, SERCA: sarcoplasmic/endoplasmic reticulum Ca2+‐adenosine triphosphatase, SR: sarcoplasmic ...
Moritz Linder, Tomas Stary, Gergő Bitay, Norbert Nagy, Axel Loewe   +4 more
wiley   +1 more source

Research progress on application of virtual reality technology in rehabilitation training for patients undergoing maintenance hemodialysis

Huli yanjiu
It summarized the general situation of virtual reality, reviewed the application of virtual reality in the rehabilitation training of patients undergoing maintenance hemodialysis and the future development trends, aiming to provide a reference for the ...
HU Shihai, QI Siyuan, YANG Qianqian, WANG Li'na   +3 more
doaj  

Mitochondrial Abnormalities of T Lymphocytes in Patients With Maintenance Hemodialysis. [PDF]

Immun Inflamm Dis
Luo C, Bao S, Bian X, Bao L, Ji C, Ma J, Huang J.   +6 more
europepmc   +1 more source

Intraoperative Collection of Ascitic Fluid With Intra‐ or Postoperative Reinfusion in Ovarian Cancer: Safety and Feasibility of a Roller Pumping Method

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 371-376, June 2026.
ABSTRACT Introduction Patients with ovarian cancer often present with massive ascites, leading to significant protein loss during surgical procedures. Although cell‐free concentrated ascites reinfusion therapy (CART) is used in palliative settings to mitigate protein loss, its application in intraoperative settings remains unexplored.
Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami   +7 more
wiley   +1 more source

Effect of hemoperfusion plus hemodialysis on uremic toxins and anemia in patients with maintenance hemodialysis. [PDF]

Ren Fail
Zou LX, Wang X, Qian CH, Zheng XQ, Sun L.   +4 more
europepmc   +1 more source

Does an Apple (or Many) Each Day, Keep Mortality Away? [PDF]

, 2019
Moorthi, Ranjani N.
core   +1 more source

Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 309-322, June 2026.
ABSTRACT Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving maintenance dialysis, driven by calcium and phosphate metabolism disturbances. Calcimimetics are central to the management of SHPT by enhancing calcium‐sensing receptor sensitivity and reducing parathyroid hormone secretion.
Fumihiko Koiwa, Daisuke Honda, Seigo Akari, Tadao Akizawa   +3 more
wiley   +1 more source

Development and Validation of a Nomogram Model for Accurately Predicting Depression in Maintenance Hemodialysis Patients: A Multicenter Cross-Sectional Study in China

Risk Management and Healthcare Policy
Xinyuan Zhou,1,2,* Fuxiang Zhu3,* 1Department of Nephrology, the First People’s Hospital of Pinghu, Jiaxing, Zhejiang, People’s Republic of China; 2Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Hangzhou ...
Zhou X, Zhu F
doaj  

Development and validation of a physical fatigue assessment scale for patients undergoing maintenance hemodialysis. [PDF]

BMC Nephrol
Shi J, Zhang H, Fang Z, Zhao D, Zheng C, Liu T, Tao X.   +6 more
europepmc   +1 more source

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic ...
Thomas Nicholson, Sophie L. Allen, Jonathan I. Quinlan, Amritpal Dhaliwal, Michael Macleod, Joshua Price, Jon Hazeldine, Michael S. Sagmeister, Caitlin Ditchfield, Kirsty C. McGee, Felicity R. Williams, Ahmed M. Elsharkawy, Matthew J. Armstrong, Carolyn A. Greig, Janet M. Lord, Leigh Breen, Simon W. Jones   +16 more
wiley   +1 more source